CD274 and non-small cell lung carcinoma: Antibody-mediated blockade of programmed cell death protein 1 (PD-1) or cell-surface localized programmed cell death-ligand 1 (PD-L1) provides a novel therapeutic paradigm for patients with advanced NSCLC.